Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

Not Applicable

Completed

Conditions: Cancer
Solid Tumors

Interventions: Procedure: HR PEM Scan

First Posted Date: 2009-11-06

Last Posted Date: 2014-08-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT01008930

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Markers of Response to Intravesical Bladder Cancer Therapy

Completed

Conditions: Bladder Cancer

First Posted Date: 2009-11-03

Last Posted Date: 2016-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT01007058

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients

Not Applicable

Withdrawn

Conditions: Advanced Cancers
Melanoma

Interventions: Procedure: Tumor Interstitial Fluid Pressure (IFP) assessments
Device: Transducer-catheter SPC-320 + Amplifier

First Posted Date: 2009-10-29

Last Posted Date: 2012-02-22

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01003626

Autologous Transplantation for Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Imatinib Mesylate
Procedure: Autologous Stem Cell Transplantation

First Posted Date: 2009-10-28

Last Posted Date: 2011-11-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT01003054

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Thrombocytopenia
Fever
Night Sweats
Chronic Lymphocytic Leukemia
Fatigue
Lymphadenopathy
Paraproteinemia
Small Lymphocytic Lymphoma
Hypogammaglobulinemia
Lymphocytosis

Interventions: Drug: Lenalidomide
Biological: Ofatumumab

First Posted Date: 2009-10-27

Last Posted Date: 2019-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT01002755

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Eltrombopag for Post Transplant Thrombocytopenia

Phase 2

Completed

Conditions: Thrombocytopenia

Interventions: Drug: Eltrombopag
Drug: Placebo

First Posted Date: 2009-10-22

Last Posted Date: 2023-09-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT01000051

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Recruiting

Conditions: Esophageal Carcinoma
Hematopoietic and Lymphoid Cell Neoplasm
Lung Carcinoma
Malignant Digestive System Neoplasm
Breast Carcinoma
Malignant Central Nervous System Neoplasm
Head and Neck Carcinoma
Malignant Solid Neoplasm
Genitourinary System Carcinoma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2009-10-07

Last Posted Date: 2025-06-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5000

Registration Number: NCT00991094

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Leukemia
Acute Lymphoblastic Leukemia
Allogeneic Haematopoietic Stem Cell Transplantation
Lymphoma

Interventions: Drug: Busulfan
Drug: Clofarabine
Drug: Thymoglobulin
Procedure: Stem Cell Transplant

First Posted Date: 2009-10-06

Last Posted Date: 2018-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT00990249

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

Not Applicable

Conditions: Colorectal Cancer

Interventions: Behavioral: Exercise Program
Behavioral: Telephone-based intervention
Other: Counseling intervention
Other: Questionnaire administration
Behavioral: Relaxation Program

First Posted Date: 2009-09-28

Last Posted Date: 2022-03-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 154

Registration Number: NCT00985400

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Procedure: Surgery
Radiation: Chest Irradiation
Drug: Cisplatin
Drug: Etoposide
Radiation: Prophylactic Cranial Irradiation

First Posted Date: 2009-09-25

Last Posted Date: 2016-06-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00984997

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy